rFVIIai in acute coronary syndromes

Seminars in Vascular Medicine

Volumn 3, Issue 2, 2003, Pages 199-204

  Sorensen, Brit Binow ^a   Hedner, Ulla ^a   Erhardtsen, Elisabeth ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Endotoxin; Inactivated FVIla; PTCA; Reperfusion; Tissue factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACTIVE SITE INACTIVATED RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING INHIBITOR; ENDOTOXIN; FIBRIN; HEMOSTATIC AGENT; HEPARIN; HIRUDIN; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STAT PROTEIN; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL WALL; BOLUS INJECTION; CALCULATION; CELL SURFACE; CLINICAL TRIAL; COMPLEX FORMATION; CYTOKINE RELEASE; DISEASE MODEL; DISSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM INJURY; ENZYME PHOSPHORYLATION; FIBRIN DEPOSITION; GINGIVA BLEEDING; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEMATOMA; HEMOSTASIS; HUMAN; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR PATENCY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; BLOOD COAGULATION; FACTOR VIIA; FACTOR XA; FIBRINOLYTIC AGENTS; HEMOSTATICS; HUMANS; LIPOPROTEINS; MYOCARDIAL REPERFUSION INJURY; RECOMBINANT PROTEINS; SEPSIS; THROMBOPLASTIN; THROMBOSIS;

EID: 0041973841     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40678     Document Type: Article

References (47)

1. Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992;12:1111-1121
2. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a 'prima ballerina.' Thromb Haemost 1995;74:7-17
3. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996;77:1877-1883
4. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma - correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295-301
5. Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 1996;83:307-320
6. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000;96:170-175
7. Lupu F, Westmuckett AD, Taylor FB Jr. Cell and tissue-specific expression of tissue factor pathway proteins in a baboon model of lethal E. coli sepsis. Blood 2002;100:496a
8. Siggiqui FA, Desai H, Amirkhosravi A, et al. Platelet microparticles from healthy donors contain tissue factor. Blood 2002;100:1936
9. Monroe D, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-1389
10. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-547
11. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995;86:1794-1801
12. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis 1996;7:459-464
13. Kjalke M, Oliver JA, Monroe DM, et al. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost 1997;78:1202-1208
14. Sorensen BB, Persson E, Freskgaard PO, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997;272:11863-11868
15. Hansen CB, Pyke C, Petersen LC, Rao LVM. Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood 2001;97:1712-1720
16. Golino P, Ragni M, Cirillo P, et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998;82:39-46
17. Pendurthi UR, Rao LVM. Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. In: Litwick G, ed. Vitamins and Hormones - Advances in Research and Applications. San Diego, CA: Academic Press; 2002:323-355
18. 2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995;270:4650-4660
19. Poulsen LK, Jacobsen N, Sorensen BB, et al. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998;273:6228-6232
20. Versteeg HH, Hoedemaeker I, Diks SH, et al. Factor VIIa/ tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem 2000;275:28750-28756
21. Taniguchi T, Kakkar AK, Tuddenham EGD, Williamson RCN, Lemoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998;58:4461-4467
22. Camerer E, Rottingen JA, Gjernes E, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999;274:32225-32233
23. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000;275:6580-6585
24. Pendurthi UR, Allen KE, Ezban M, Rao LVM. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa center dot tissue factor-induced signal transduction. J Biol Chem 2000;275:14632-14641
25. Pendurthi UR, Alok D, Rao LV. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly(A) polymerase. Proc Natl Acad Sci USA 1997;94:12598-12603
26. Martin P. Wound healing - aiming for perfect skin regeneration. Science 1997;276:75-81
27. Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27:605-617
28. Taylor FB, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-134
29. Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y. Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. Crit Care Med 1997;25:1820-1826
30. Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995;74:464-472
31. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-3050
32. Sanchez-Gomez A, Casani L, Vilahur G, Badimon L. FFR-rFVIIa inhibits thrombosis triggered by ruptured and eroded vessel wall. Thromb Haemost 2001;Suppl July: OC999
33. Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997;25:341-346
34. Holst J, Kristensen AT, Kristensen HI, Ezban M, Hedner U. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model. Eur J Vasc Endovasc Surg 1998;15:515-520
35. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146:419-428
36. Kranzhofer R, Clinton SK, Ishii K, Coughlin SR, Fenton II, Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res 1996;79:286-294
37. Ma XL, Lefer DJ, Lefer AM, Rothlein R. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation 1992;86:937-946
38. Golino P, Ragni M, Cirillo P, et al. Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction. Blood Coagul Fibrinolysis 2000;11:S149-S158
39. Erlich JH, Boyle EM, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000;157:1849-1862
40. Osterholm C, Qi ZQ, Ekberg J, et al. Initial inhibition of tissue factor signalling reduces chronic vascular changes in isogenic rat aortic transplants. Am J Transplant 2001;1:29-37
41. Taylor FB. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 1996;26(suppl 1):83-91
42. Creasey AA, Chang AC, Feigen L, Wün TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2856
43. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998;91:1609-1615
44. Erhardtsen E, Nilsson P, Johannessen M, Thomsen MS. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001;41:880-885
45. Lincoff AM. First clinical investigation of a tissue factor inhibitor administered during percutaneous coronary revascularizatoin: a randomized, double-blinded, dose-escalation trial - assessing safety and efficacy of FFR-rFVIIa in PTCA (ASIS) trial. Presentation of Late Breaking Clinical Trials in Interventional Cardiology at ACCIS 2000, March 2000
46. Lev EI, Marmur JD, Zdravkovic M, et al. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Arterioscler Thromb Vasc Biol 2002;22:1036-1041
47. Jilma B, Marsik C, Mayr F, et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002;72:403-410